<DOC>
	<DOCNO>NCT00331604</DOCNO>
	<brief_summary>This trial conduct Asia , Europe South America . The aim research compare efficacy ( reduction HbA1c blood glucose ) pulmonary safety ( pulmonary function test , chest x-ray ) mealtime inhale insulin subcutaneous insulin aspart combination insulin detemir Type 2 Diabetes .</brief_summary>
	<brief_title>Safety Efficacy Inhaled Insulin Type 2 Diabetes</brief_title>
	<detailed_description>The decision discontinue development AERxÂ® due safety concern . An analysis conclude fast-acting inhaled insulin form know today , unlikely offer significant clinical convenience benefit injection modern insulin pen device .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 2 diabetes Currently treat insulin Body mass index ( BMI ) less equal 40.0 kg/m2 HbA1c le equal 11.0 % Total daily insulin dosage less equal 100 IU U/day Current smoke smoking within last 6 month Cardiac problem Uncontrolled hypertension Current proliferative retinopathy maculopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>